ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines

- Extension financing led by new investor Bpifrance, with renewed participation from all existing shareholders, AdBio Partners, CDTI Innovación, Columbus Venture Partners, European Innovation Council (EIC), Hadean Ventures, Invivo Partners and Sound Bioventures - - Proceeds to support...